Silence Therapeutics plc

Declaration of Voting Results & Voting Rights Announcements • Nov 20, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5694T

Silence Therapeutics PLC

20 November 2013

20 November 2013

Grant of Options and Additional Listing

On 19 November 2013, Tim Freeborn (Finance Director and Company Secretary) and Annie Cheng (Chief Operating Officer) were granted 40,000 and 76,000 options respectively over ordinary shares of 5 pence. The share options, granted at nil consideration, will vest after three years and are exercisable at 282 pence per share (the previous day's closing price), and are subject to a 400p hurdle price.

Following this grant of these options, Tim Freeborn and Annie Cheng hold the following total number of options over ordinary shares of Silence Therapeutics:

	No. of Options
Tim Freeborn	310,000
Annie Cheng	140,000

The Company also announces that it has applied to AIM for the admission to trading of 48,000 Ordinary Shares of 5 pence each in the company.  These shares are being issued in respect of an exercise of options under the Employee Share Scheme, at an exercise price of 90 pence per share.

Admission of these shares is expected to take place on Monday 25 November 2013. The total number of shares in issue, following admission, will be 47,061,554.

For further information please contact:

Silence Therapeutics plc Ali Mortazavi, Chief Executive	+44 (0)333 988 0140 [email protected]
Timothy Freeborn, Finance Director	[email protected]
Annie Cheng, Chief Operating Officer	[email protected]
Canaccord Genuity Limited	+44 (0)20 7523 8350
Lucy Tilley Dr Julian Feneley Henry Fitzgerald-O'Connor

This information is provided by RNS

The company news service from the London Stock Exchange

END

LISEAKFEASNDFFF